Halozyme Therapeutics Stock Price History
| HALO Stock | USD 65.16 0.84 1.31% |
Below is the normalized historical share price chart for Halozyme Therapeutics extending back to March 12, 2004. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Halozyme Therapeutics stands at 65.16, as last reported on the 22nd of March, with the highest price reaching 65.21 and the lowest price hitting 63.50 during the day.
If you're considering investing in Halozyme Stock, it is important to understand the factors that can impact its price. Halozyme Therapeutics appears to be very steady, given 3 months investment horizon. Halozyme Therapeutics holds Efficiency (Sharpe) Ratio of 0.39, which attests that the entity had a 0.39 % return per unit of risk over the last 3 months. By evaluating Halozyme Therapeutics' technical indicators, you can evaluate if the expected return of 0.55% is justified by implied risk. Please utilize Halozyme Therapeutics' Market Risk Adjusted Performance of 0.9106, downside deviation of 1.17, and Risk Adjusted Performance of 0.2868 to validate if our risk estimates are consistent with your expectations.
At this time, Halozyme Therapeutics' Total Stockholder Equity is very stable compared to the past year. As of the 22nd of March 2025, Liabilities And Stockholders Equity is likely to grow to about 2.2 B, while Common Stock Total Equity is likely to drop about 104.5 K. . At this time, Halozyme Therapeutics' Price Earnings Ratio is very stable compared to the past year. As of the 22nd of March 2025, Price To Operating Cash Flows Ratio is likely to grow to 13.29, while Price To Sales Ratio is likely to drop 5.67. Halozyme Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 16th of March 2004 | 200 Day MA 54.6813 | 50 Day MA 57.7854 | Beta 1.323 |
Halozyme |
Sharpe Ratio = 0.3918
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HALO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.4 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.55 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.39 actual daily | 30 70% of assets perform better |
Based on monthly moving average Halozyme Therapeutics is performing at about 30% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Halozyme Therapeutics by adding it to a well-diversified portfolio.
Price Book 21.8395 | Enterprise Value Ebitda 13.488 | Price Sales 7.8257 | Shares Float 121.8 M | Wall Street Target Price 66.1111 |
Halozyme Therapeutics Stock Price History Chart
There are several ways to analyze Halozyme Stock price data. The simplest method is using a basic Halozyme candlestick price chart, which shows Halozyme Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | March 21, 2025 | 65.16 |
| Lowest Price | December 20, 2024 | 46.96 |
Halozyme Therapeutics March 22, 2025 Stock Price Synopsis
Various analyses of Halozyme Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Halozyme Stock. It can be used to describe the percentage change in the price of Halozyme Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Halozyme Stock.| Halozyme Therapeutics Accumulation Distribution | 104,919 | |
| Halozyme Therapeutics Price Action Indicator | 1.23 | |
| Halozyme Therapeutics Price Daily Balance Of Power | 0.49 | |
| Halozyme Therapeutics Price Rate Of Daily Change | 1.01 |
Halozyme Therapeutics March 22, 2025 Stock Price Analysis
Halozyme Stock Price History Data
The price series of Halozyme Therapeutics for the period between Sun, Dec 22, 2024 and Sat, Mar 22, 2025 has a statistical range of 17.48 with a coefficient of variation of 8.94. Under current investment horizon, the daily prices are spread out with arithmetic mean of 55.39. The median price for the last 90 days is 56.64. The company completed 171:40 stock split on 10th of December 2003.| Open | High | Low | Close | Volume | ||
| 03/21/2025 | 64.32 | 65.21 | 63.50 | 65.16 | 4,001,029 | |
| 03/20/2025 | 63.91 | 64.94 | 63.88 | 64.32 | 1,637,283 | |
| 03/19/2025 | 62.59 | 64.55 | 62.52 | 64.30 | 1,371,655 | |
| 03/18/2025 | 62.62 | 63.18 | 62.13 | 62.54 | 1,226,195 | |
| 03/17/2025 | 62.46 | 63.39 | 60.92 | 62.95 | 1,587,074 | |
| 03/14/2025 | 61.22 | 62.72 | 61.11 | 62.27 | 1,042,448 | |
| 03/13/2025 | 60.77 | 61.48 | 60.44 | 61.06 | 992,126 | |
| 03/12/2025 | 61.47 | 62.03 | 60.38 | 60.89 | 1,525,372 | |
| 03/11/2025 | 61.24 | 62.39 | 60.65 | 61.45 | 1,218,119 | |
| 03/10/2025 | 60.17 | 63.11 | 60.14 | 61.44 | 2,090,911 | |
| 03/07/2025 | 59.77 | 61.49 | 59.18 | 60.98 | 1,491,687 | |
| 03/06/2025 | 59.21 | 60.31 | 59.17 | 60.15 | 1,753,270 | |
| 03/05/2025 | 58.23 | 60.07 | 58.23 | 59.53 | 1,714,544 | |
| 03/04/2025 | 57.57 | 58.66 | 56.90 | 58.14 | 1,478,544 | |
| 03/03/2025 | 59.14 | 59.90 | 57.66 | 57.96 | 1,414,542 | |
| 02/28/2025 | 57.55 | 59.16 | 57.49 | 59.15 | 1,235,596 | |
| 02/27/2025 | 57.99 | 58.97 | 57.65 | 57.70 | 879,988 | |
| 02/26/2025 | 58.02 | 58.70 | 57.45 | 57.92 | 1,024,737 | |
| 02/25/2025 | 58.60 | 58.98 | 57.50 | 57.99 | 1,198,241 | |
| 02/24/2025 | 57.93 | 59.35 | 57.49 | 58.50 | 1,362,433 | |
| 02/21/2025 | 58.00 | 58.74 | 57.32 | 57.75 | 1,299,528 | |
| 02/20/2025 | 57.35 | 57.73 | 56.07 | 57.44 | 1,543,386 | |
| 02/19/2025 | 58.98 | 60.67 | 56.77 | 57.77 | 2,236,460 | |
| 02/18/2025 | 58.84 | 58.90 | 57.61 | 57.90 | 1,657,369 | |
| 02/14/2025 | 59.12 | 59.40 | 58.12 | 58.29 | 1,000,607 | |
| 02/13/2025 | 58.48 | 58.72 | 57.79 | 58.61 | 883,113 | |
| 02/12/2025 | 56.71 | 58.33 | 56.71 | 58.11 | 888,165 | |
| 02/11/2025 | 57.02 | 57.39 | 56.51 | 57.33 | 1,143,541 | |
| 02/10/2025 | 57.10 | 57.78 | 56.88 | 57.34 | 967,321 | |
| 02/07/2025 | 58.07 | 58.07 | 56.94 | 57.10 | 1,042,698 | |
| 02/06/2025 | 57.91 | 58.20 | 57.46 | 57.94 | 1,068,187 | |
| 02/05/2025 | 57.05 | 57.72 | 56.60 | 57.63 | 1,052,607 | |
| 02/04/2025 | 56.01 | 56.85 | 55.93 | 56.77 | 716,947 | |
| 02/03/2025 | 55.12 | 57.14 | 54.96 | 56.28 | 1,136,916 | |
| 01/31/2025 | 56.34 | 57.40 | 56.32 | 56.64 | 1,385,895 | |
| 01/30/2025 | 56.30 | 57.46 | 56.06 | 56.42 | 1,058,672 | |
| 01/29/2025 | 56.03 | 56.74 | 55.12 | 55.83 | 840,902 | |
| 01/28/2025 | 55.97 | 56.82 | 55.66 | 56.00 | 1,233,861 | |
| 01/27/2025 | 55.69 | 57.25 | 55.24 | 55.86 | 913,908 | |
| 01/24/2025 | 55.29 | 56.08 | 54.98 | 55.77 | 731,809 | |
| 01/23/2025 | 55.22 | 55.87 | 54.96 | 55.63 | 934,843 | |
| 01/22/2025 | 55.79 | 56.00 | 54.99 | 55.28 | 1,154,629 | |
| 01/21/2025 | 55.10 | 56.39 | 54.88 | 55.94 | 1,204,322 | |
| 01/17/2025 | 55.66 | 55.73 | 54.77 | 54.80 | 942,149 | |
| 01/16/2025 | 54.64 | 55.79 | 54.64 | 55.37 | 1,570,052 | |
| 01/15/2025 | 54.39 | 55.30 | 54.05 | 54.51 | 1,959,521 | |
| 01/14/2025 | 54.74 | 54.87 | 53.26 | 53.83 | 1,360,890 | |
| 01/13/2025 | 52.65 | 54.84 | 52.23 | 54.14 | 2,016,142 | |
| 01/10/2025 | 53.95 | 53.99 | 52.66 | 52.80 | 2,146,563 | |
| 01/08/2025 | 54.12 | 55.00 | 51.91 | 53.76 | 2,669,896 | |
| 01/07/2025 | 51.00 | 51.73 | 50.36 | 51.19 | 1,790,512 | |
| 01/06/2025 | 47.75 | 50.82 | 47.75 | 50.51 | 1,894,141 | |
| 01/03/2025 | 48.20 | 48.53 | 47.52 | 47.74 | 992,979 | |
| 01/02/2025 | 48.23 | 49.00 | 47.86 | 48.01 | 1,210,331 | |
| 12/31/2024 | 48.20 | 48.72 | 47.72 | 47.81 | 842,690 | |
| 12/30/2024 | 48.65 | 48.80 | 47.65 | 47.99 | 891,545 | |
| 12/27/2024 | 47.60 | 48.26 | 47.56 | 48.13 | 946,090 | |
| 12/26/2024 | 47.47 | 48.24 | 47.00 | 48.03 | 762,337 | |
| 12/24/2024 | 47.25 | 47.63 | 46.76 | 47.54 | 308,684 | |
| 12/23/2024 | 46.77 | 47.34 | 46.26 | 47.16 | 1,451,779 | |
| 12/20/2024 | 47.03 | 48.21 | 46.88 | 46.96 | 4,794,826 |
About Halozyme Therapeutics Stock history
Halozyme Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Halozyme is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Halozyme Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Halozyme Therapeutics stock prices may prove useful in developing a viable investing in Halozyme Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 129.4 M | 106.3 M | |
| Net Income Applicable To Common Shares | 232.4 M | 244.1 M |
Halozyme Therapeutics Quarterly Net Working Capital |
|
Halozyme Therapeutics Stock Technical Analysis
Halozyme Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Halozyme Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Halozyme Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Halozyme Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Halozyme to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.2868 | |||
| Jensen Alpha | 0.4861 | |||
| Total Risk Alpha | 0.5675 | |||
| Sortino Ratio | 0.4462 | |||
| Treynor Ratio | 0.9006 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.623 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.